The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients
Open accessAbstract
BACKGROUND: Everolimus, a novel proliferation inhibitor and immunosuppressive agent, may suppress cardiac-allograft vasculopathy. We conducted a randomized, double-blind, clinical trial comparing everolimus with azathioprine in recipients of a first heart transplant. METHODS: A total of 634 patients were randomly assigned to receive 1.5 mg of everolimus per day (209 patients), 3.0 mg of everolimus per day (211 patients), or 1.0 to 3.0 mg of azathioprine per kilogram of body weight per day (214 patients), in combination with cyclosporine, corticosteroids, and statins. The primary efficacy end point was a composite of death, graft loss or retransplantation, loss to follow-up, biopsy-proved acute rejection of grade 3A, or rejection with hemodynamic compromise. RESULTS: At six months, the percentage of patients who had reached the primary efficacy end point was significantly smaller in the group given 3.0 mg of everolimus (27.0 percent, P<0.001) and the group given 1.5 mg of everolimus (36.4 percent, P=0.03) than in the azathioprine group (46.7 percent). Intravascular ultrasonography showed that the average increase in maximal intimal thickness 12 months after transplantation was significantly smaller in the two everolimus groups than in the azathioprine group. The incidence of vasculopathy was also significantly lower in the 1.5-mg group (35.7 percent, P=0.045) and the 3.0-mg group (30.4 percent, P=0.01) than in the azathioprine group (52.8 percent). The rates of cytomegalovirus infection were significantly lower in the 1.5-mg group (7.7 percent, P<0.001) and the 3.0-mg group (7.6 percent, P<0.001) than in the azathioprine group (21.5 percent). Rates of bacterial infection were significantly higher in the 3.0-mg group than in the azathioprine group. Serum creatinine levels were also significantly higher in the two everolimus groups than in the azathioprine group. CONCLUSIONS: Everolimus was more efficacious than azathioprine in reducing the severity and incidence of cardiac-allograft vasculopathy, suggesting that everolimus therapy may alleviate this serious problem.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
J Heart Lung Transplant 2021;40(4).
(2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.002 · Cited by 6,665
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Mintz, G. S., Nissen, S. E., Anderson, W. D., Bailey, S. R., Erbel, R., Fitzgerald, P. J., Pinto, F. J., Rosenfield, K., Siegel, R. J., Tuzcu, E. M., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01175-5 · Cited by 2,185
Self-citationBillingham, M. E., Cary, N. R. B., Hammond, M. E. H., Kemnitz, J., Marboe, C. C., Mccallister, H. A., Snovar, D. C., Winters, G. L., & Zerbe, A. (1990) · PubMed · Cited by 1,490
Effect of pravastatin on outcomes after cardiac transplantation
Kobashigawa, J. A., Katznelson, S., Laks, H., Johnson, J. A., Yeatman, L., Wang, X. M., Chia, D., Terasaki, P. I., Sabad, A., Cogert, G. A., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509073331003 · Cited by 1,301
Self-citationCytomegalovirus Infection Is Associated With Cardiac Allograft Rejection and Atherosclerosis
Grattan, M. T. (1989) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1989.03420240075030 · Cited by 968
IMMUNOPHARMACOLOGY OF RAPAMYCIN
Abraham, R. T., & Wiederrecht, G. J. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.483 · Cited by 653
A RANDOMIZED ACTIVE-CONTROLLED TRIAL OF MYCOPHENOLATE MOFETIL IN HEART TRANSPLANT RECIPIENTS1
Kobashigawa, J., Miller, L., Renlund, D., Mentzer, R., Alderman, E., Bourge, R., Costanzo, M., Eisen, H., Dureau, G., Ratkovec, R., et al. (1998) · Transplantation · doi:10.1097/00007890-199808270-00016 · Cited by 615
Self-citation
Cited by
Nissen, S. E., Nicholls, S. J., Sipahi, I., Libby, P., Raichlen, J. S., Ballantyne, C. M., Davignon, J., Erbel, R., Fruchart, J. C., Tardif, J.-C., et al. (2006) · JAMA · doi:10.1001/jama.295.13.jpc60002 · Cited by 2,047
Self-citationNissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707
Self-citationCostanzo, M. R., Costanzo, M. R., Dipchand, A., Starling, R., Anderson, A., Chan, M., Desai, S., Fedson, S., Fisher, P., Gonzales-Stawinski, G., et al. (2010) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2010.05.034 · Cited by 1,653
Self-citationImmunosuppressive Drugs for Kidney Transplantation
Halloran, P. F. (2004) · New England Journal of Medicine · doi:10.1056/nejmra033540 · Cited by 1,555
Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Crowe, T., Sasiela, W. J., Tsai, J., Orazem, J., Magorien, R. D., O'Shaughnessy, C., & Ganz, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042000 · Cited by 1,325
Self-citationVigneri, P., Frasca, F., Sciacca, L., Pandini, G., & Vigneri, R. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0087 · Cited by 1,009
Microbial drug discovery: 80 years of progress
Demain, A. L., & Sanchez, S. (2009) · The Journal of Antibiotics · doi:10.1038/ja.2008.16 · Cited by 1,002
Immunoregulatory functions of mTOR inhibition
Thomson, A. W., Turnquist, H. R., & Raimondi, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2546 · Cited by 847
Chambers, D. C., Perch, M., Zuckermann, A., Cherikh, W. S., Harhay, M. O., Hayes, D., Hsich, E., Khush, K. K., Potena, L., Sadavarte, A., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.021 · Cited by 596
Cardiac Allograft Vasculopathy: Recent Developments
Schmauss, D., & Weis, M. (2008) · Circulation · doi:10.1161/circulationaha.107.711911 · Cited by 587
Stone, G. W. (2008) · JAMA · doi:10.1001/jama.299.16.1903 · Cited by 582
Khush, K. K., Cherikh, W. S., Chambers, D. C., Goldfarb, S., Hayes, D., Kucheryavaya, A. Y., Levvey, B. J., Meiser, B., Rossano, J. W., & Stehlik, J. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2018.07.022 · Cited by 555
Deng, M. C., Eisen, H. J., Mehra, M. R., Billingham, M., Marboe, C. C., Berry, G., Kobashigawa, J., Johnson, F. L., Starling, R. C., Murali, S., et al. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01175.x · Cited by 524
Self-citationNew Insights Into the Role of mTOR Signaling in the Cardiovascular System
Sciarretta, S., Forte, M., Frati, G., & Sadoshima, J. (2018) · Circulation Research · doi:10.1161/circresaha.117.311147 · Cited by 491
O'Donnell, A., Faivre, S., Burris, H. A., Rea, D., Papadimitrakopoulou, V., Shand, N., Lane, H. A., Hazell, K., Zoellner, U., Kovarik, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0988 · Cited by 479
Keogh, A., Richardson, M., Ruygrok, P., Spratt, P., Galbraith, A., O’Driscoll, G., Macdonald, P., Esmore, D., Muller, D., & Faddy, S. (2004) · Circulation · doi:10.1161/01.cir.0000136812.90177.94 · Cited by 463
Mitochondrial autophagy: molecular mechanisms and implications for cardiovascular disease
Li, A., Gao, M., Liu, B., Qin, Y., chen, L., Liu, H., Wu, H., & Gong, G. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-04906-6 · Cited by 456
Taylor, A. L., Watson, C. J. E., & Bradley, J. A. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.03.012 · Cited by 445
de Ferranti, S. D., Steinberger, J., Ameduri, R., Baker, A., Gooding, H., Kelly, A. S., Mietus-Snyder, M., Mitsnefes, M. M., Peterson, A. L., St-Pierre, J., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000618 · Cited by 441
Effect of ACAT Inhibition on the Progression of Coronary Atherosclerosis
Nissen, S. E., Tuzcu, E. M., Brewer, H. B., Sipahi, I., Nicholls, S. J., Ganz, P., Schoenhagen, P., Waters, D. D., Pepine, C. J., Crowe, T. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054699 · Cited by 398
Self-citationUpstream of the mammalian target of rapamycin: do all roads pass through mTOR?
Corradetti, M. N., & Guan, K.-L. (2006) · Oncogene · doi:10.1038/sj.onc.1209885 · Cited by 386
Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome
Canaud, G., Bienaimé, F., Tabarin, F., Bataillon, G., Seilhean, D., Noël, L.-H., Dragon-Durey, M.-A., Snanoudj, R., Friedlander, G., Halbwachs-Mecarelli, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312890 · Cited by 355
Kobashigawa, J. A., Miller, L. W., Russell, S. D., Ewald, G. A., Zucker, M. J., Goldberg, L. R., Eisen, H. J., Salm, K., Tolzman, D., Gao, J., et al. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01290.x · Cited by 329
Self-citationKhush, K. K., Hsich, E., Potena, L., Cherikh, W. S., Chambers, D. C., Harhay, M. O., Hayes, D., Perch, M., Sadavarte, A., Toll, A., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.015 · Cited by 305
Yee, K. W. L., Zeng, Z., Konopleva, M., Verstovsek, S., Ravandi, F., Ferrajoli, A., Thomas, D., Wierda, W., Apostolidou, E., Albitar, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0764 · Cited by 285
Tuzcu, E. M., Kapadia, S. R., Sachar, R., Ziada, K. M., Crowe, T. D., Feng, J., Magyar, W. A., Hobbs, R. E., Starling, R. C., Young, J. B., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.12.076 · Cited by 285
Self-citationChih, S., Chong, A. Y., Mielniczuk, L. M., Bhatt, D. L., & Beanlands, R. S. B. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.04.033 · Cited by 281
Cardiac allograft vasculopathy after heart transplantation: risk factors and management
Valantine, H. (2004) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2004.03.009 · Cited by 269
Organ transplantation: historical perspective and current practice
Watson, C. J. E., & Dark, J. H. (2012) · British Journal of Anaesthesia · doi:10.1093/bja/aer384 · Cited by 261
Eisen, H. J., Kobashigawa, J., Keogh, A., Bourge, R., Renlund, D., Mentzer, R., Alderman, E., Valantine, H., Dureau, G., Mancini, D., et al. (2005) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2005.02.002 · Cited by 259
Self-citationA Randomized Controlled Trial of Tacrolimus Versus Cyclosporine After Lung Transplantation
Hachem, R. R., Yusen, R. D., Chakinala, M. M., Meyers, B. F., Lynch, J. P., Aloush, A. A., Patterson, G. A., & Trulock, E. P. (2007) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2007.07.027 · Cited by 160
Fox, J. H., Connor, T., Chopra, V., Dorsey, K., Kama, J. A., Bleckmann, D., Betschart, C., Hoyer, D., Frentzel, S., DiFiglia, M., et al. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-26 · Cited by 94
“However, the class of mTOR-kinase-inhibiting drugs is well characterized and in clinical use for their anti-neoplastic and anti-solid organ graft rejection effects [18,19].”
BackgroundEpileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy
Aronica, E., Specchio, N., Luinenburg, M. J., & Curatolo, P. (2023) · Brain · doi:10.1093/brain/awad048 · Cited by 74
AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game
Canaud, G., Legendre, C., & Terzi, F. (2015) · Lupus · doi:10.1177/0961203315569336 · Cited by 32
Metadata
- Authors
- Eisen, H. J., Tuzcu, E. M., Dorent, R., Kobashigawa, J., Mancini, D., Valantine-von Kaeppler, H. A., Starling, R. C., Sørensen, K., Hummel, M., Lind, J. M., Abeywickrama, K. H., & Bernhardt, P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-08-28
- Volume
- 349
- Issue
- 9
- Pages
- 847-858
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2122783053
- Cited by
- 1,198
- References
- 26
- FWCI
- 85.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.